Anna-Maria Lazaratos

6PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersInnate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.

Matthew Dankner, Laurie-Rose Dubé, Mark Sorin

|Jul 11, 2025
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils.

John Heath, Ryuhjin Ahn, Valerie Sabourin

|Jan 27, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.

Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca

|Jan 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda

|Oct 25, 2024
Antibody-Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases.

David J H Bian, Sara F Cohen, Anna-Maria Lazaratos

|Aug 09, 2023
FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair.

Edgar Pinedo-Carpio, Julien Dessapt, Adèle Beneyton

Pageof 1

Frequent Collaborators

4 joint publications

Matthew Dankner

2 joint publications

Alexander Nowakowski

1 joint publications

John Heath

1 joint publications

Ryuhjin Ahn